Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 755

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 755
---
 common share equivalents (or a combination of units thereof) involving a variable rate transaction. The offering resulted in gross proceeds to the Company of $ 1,750,000and expenses of approximately $ 321,000. Warrants On October 9, 2024, the Company and certain existing warrant holders entered into warrant amendment agreements, or collectively, the Amendment, to amend those warrants issued by Company to such holders, collectively, to purchase up to 105,843Common Shares issued to such holders, or the Existing Warrants. The Amendment makes certain Annex F-23 NLS PHARMACEUTICS LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

adjustment to the definition of a “Fundamental Transaction” in Section 3(e) of the Existing Warrants. In exchange for the Amendment, the Company agreed to adjust the exercise price in the Common Warrants to CHF 0.80and issued to the holders Pre -FundedWarrants to purchase up to 136,648Common Shares, or the Pre -FundedWarrants. Each Pre -FundedWarrant is exercisable for one Common Share at an exercise price of CHF 0.80per share. The Pre -FundedWarrants are immediately exercisable and may be exercised at any time until all of the Pre -FundedWarrants are exercised in full. On September 16, 2024, the Company and an institutional investor entered into a warrant amendment agreement to amend warrants to purchase up to 172,836common shares, par value CHF 0.80. The amendment adjusted the definition of a “Fundamental Transaction” and the exercise price to CHF 0.80. Following an increase in authorized common shares, the Company will issue pre -fundedwarrants to purchase up to 191,431common shares for aggregate proceeds of $ 153,144. The Company has reflected a deemed dividend totaling $ 2,076,180for the incremental value from the modification of the warrants’ exercise price and the fair value of the warrants issued as consideration for executing the Amendment. The deemed has been reflected within stockholders’ deficit and as an increase to loss attributable to common stockholders for the purposes of computing loss per share. The incremental value due to the modification was determined to be $ 366,684using a Black -Scholesoption pricing model to compute the fair value of the warrant pre and post modification and recording the difference. The fair value of the